Medical burden in bipolar disorder: Findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE)

Bipolar Disorders

Volumn 17, Issue 2, 2015, Pages 212-223

  Sylvia, Louisa G ^a   Shelton, Richard C ^b   Kemp, David E ^c   Bernstein, Emily E ^a   Friedman, Edward S ^d   Brody, Benjamin D ^e   Mcelroy, Susan L ^f   Singh, Vivek ^g   Tohen, Mauricio ^h   Bowden, Charles L ^g   Ketter, Terence A ⁱ   Deckersbach, Thilo ^a   Thase, Michael E ^j   Reilly Harrington, Noreen A ^a   Nierenberg, Andrew A ^a   Rabideau, Dustin J ^a   Kinrys, Gustavo ^a   Kocsis, James H ^e   Bobo, William V ^k   Kamali, Masoud ^l   Mcinnis, Melvin G ^l   Calabrese, Joseph R ^c   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g Mays Cancer Center at UT Health San Antonio   (United States)

^h UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k MAYO CLINIC   (United States)

^l UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

more..

Author keywords

Bipolar disorder; Medical comorbidity; Metabolic syndrome; Mood symptoms

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; CLOMIPRAMINE; CLOZAPINE; HIGH DENSITY LIPOPROTEIN; IMIPRAMINE; LITHIUM; MIRTAZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; VALPROIC ACID; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT; TRANQUILIZER;

ADULT; ARTICLE; ASTHMA; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BODY WEIGHT DISORDER; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DRUG DEPENDENCE; DSM-IV-TR; FEMALE; HEAD INJURY; HEART INFARCTION; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOMANIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICAL HISTORY; MENTAL DISEASE; METABOLIC SYNDROME X; MIGRAINE; NEOPLASM; ONSET AGE; PREDICTOR VARIABLE; PRIORITY JOURNAL; SEIZURE; SMOKING; THYROID DISEASE; WEIGHT GAIN; BIPOLAR DISORDER; CARDIOVASCULAR DISEASES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HYPERLIPIDEMIAS; MIDDLE AGED; NEOPLASMS; PSYCHOLOGY; SEIZURES; SUBSTANCE-RELATED DISORDERS;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; ASTHMA; BIPOLAR DISORDER; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; HYPERLIPIDEMIAS; LITHIUM COMPOUNDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASMS; QUETIAPINE FUMARATE; SEIZURES; SMOKING; SUBSTANCE-RELATED DISORDERS;

EID: 84924278781     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12243     Document Type: Article

References (59)

1. Salvatore P, Tohen M, Khalsa HM et al. Longitudinal research on bipolar disorders. Epidemiol Psichiatr Soc 2007; 16: 109-117.
2. Young AH, Grunze H. Physical health of patients with bipolar disorder. Acta Psychiatr Scand Suppl 2013; 442: 3-10.
3. Coryell W, Scheftner W, Keller M et al. The enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993; 150: 720-727.
4. Sanchez-Moreno J, Martinez-Aran A, Tabares-Seisdedos R et al. Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom 2009; 78: 285-297.
5. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990; 47: 1106-1111.
6. Kemp DE, Sylvia LG, Calabrese JR et al. General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial. Acta Psychiatr Scand 2014; 129: 24-34.
7. Maina G, Bechon E, Rigardetto S, Salvi V. General medical conditions are associated with delay to treatment in patients with bipolar disorder. Psychosomatics 2013; 54: 437-442.
8. Weber NS, Fisher JA, Cowan DN et al. Psychiatric and general medical conditions comorbid with bipolar disorder in the National Hospital Discharge Survey. Psychiatr Serv 2011; 62: 1152-1158.
9. Goldstein BI, Fagiolini A, Houck P, Kupfer DJ. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord 2009; 11: 657-662.
10. Khot UN, Khot MB, Bajzer CT et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898-904.
11. McIntyre RS, Konarski JZ, Misener VL et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005; 17: 83-93.
12. Krishnan KR. Psychiatric and medical comorbidity of bipolar disorder. Psychosom Med 2005; 67: 1-8.
13. Soreca I, Fagiolini A, Frank E et al. Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. J Psychiatr Res 2008; 42: 956-961.
14. McIntyre RS, Konarski JZ, Soczynska JK et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv 2006; 57: 1140-1144.
15. Kemp DE, Gao K, Ganocy SJ et al. Medical and substance use comorbidity in bipolar disorder. J Affect Disord 2009; 116: 64-69.
16. Kupka RW, Nolen WA, Post RM et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 2002; 51: 305-311.
17. Matthews AM, Huckans MS, Blackwell AD, Hauser P. Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders. Bipolar Disord 2008; 10: 266-270.
18. van Winkel R, De Hert M, Van Eyck D et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 10: 342-348.
19. Goldstein BI, Liu SM, Zivkovic N, Schaffer A, Chien LC, Blanco C. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord 2011; 13: 387-395.
20. McElroy SL, Frye MA, Suppes T et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63: 207-213.
21. Hennekens C. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 2007; 68 (Suppl. 4): 4-7.
22. Angst F, Stassen HH, Clayton PJ et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68: 167-181.
23. Osby U, Brandt L, Correia N et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58: 844-850.
24. Fagiolini A, Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry 2009; 70 (Suppl. 3): 22-29.
25. Centorrino F, Mark TL, Talamo A et al. Health and economic burden of metabolic comorbidity among individuals with bipolar disorder. J Clin Psychopharmacol 2009; 29: 595-600.
26. Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JR. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord 2010; 12: 404-413.
27. Thompson WK, Kupfer DJ, Fagiolini A et al. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial. J Clin Psychiatry 2006; 67: 783-788.
28. Lindenmayer JP, Khan A, Kaushik S et al. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr Res 2012; 142: 171-176.
29. Gili M, Garcia-Toro M, Vives M et al. Medical comorbidity in recurrent versus first-episode depressive patients. Acta Psychiatr Scand 2011; 123: 220-227.
30. Chang HH, Yang YK, Gean PW et al. The role of valproate in metabolic disturbances in bipolar disorder patients. J Affect Disord 2010; 124: 319-323.
31. Lee NY, Kim SH, Cho B et al. Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1243-1249.
32. Serretti A, Chiesa A, Calati R et al. Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. J Psychopharmacol 2013; 27: 616-628.
33. de Almeida KM, Moreira CL, Lafer B. Metabolic syndrome and bipolar disorder: what should psychiatrists know? CNS Neurosci Ther 2012; 18: 160-166.
34. Ketter TA. Strategies for monitoring outcomes in patients with bipolar disorder. Prim Care Companion J Clin Psychiatry 2010; 12 (Suppl. 1): 10-16.
35. Ortiz A, Cervantes P, Zlotnik G et al. Cross-prevalence of migraine and bipolar disorder. Bipolar Disord 2010; 12: 397-403.
36. Lala SV, Sajatovic M. Medical and psychiatric comorbidities among elderly individuals with bipolar disorder: a literature review. J Geriatr Psychiatry Neurol 2012; 25: 20-25.
37. Kilbourne AM, Post EP, Nossek A et al. Service delivery in older patients with bipolar disorder: a review and development of a medical care model. Bipolar Disord 2008; 10: 672-683.
38. Nierenberg AN, Sylvia LG, Leon AC et al. Clinical Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder. Clin Trials 2014; 11: 114-127.
39. Suppes T, Dennehy EB, Hirschfeld RM et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005; 66: 870-886.
40. Asao K, Kao WH, Baptiste-Roberts K et al. Short stature and the risk of adiposity, insulin resistance, and type 2 diabetes in middle age: the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Diabetes Care 2006; 29: 1632-1637.
41. Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (Suppl. 20): 22-33.
42. Spearing MK, Post RM, Leverich GS et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159-171.
43. Bowden CL, Singh V, Thompson P et al. Development of the bipolar inventory of symptoms scale. Acta Psychiatr Scand 2007; 116: 189-194.
44. Gonzalez JM, Bowden CL, Katz MM et al. Development of the Bipolar Inventory of Symptoms Scale: concurrent validity, discriminant validity and retest reliability. Int J Methods Psychiatr Res 2008; 17: 198-209.
45. Leon AC, Solomon DA, Mueller TI et al. A brief assessment of psychosocial functioning of subjects with bipolar I disorder: the LIFE-RIFT. Longitudinal Interval Follow-up Evaluation-Range Impaired Functioning Tool. J Nerv Ment Dis 2000; 188: 805-812.
46. Kilbourne AM, Cornelius JR, Han X et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 2004; 6: 368-373.
47. Park YW, Zhu S, Palaniappan L et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163: 427-436.
48. Thabit H, Burns N, Shah S et al. Prevalence and predictors of diabetes and cardiometabolic risk among construction workers in Ireland: the Construction Workers Health Trust screening study. Diab Vasc Dis Res 2013; 10: 337-345.
49. Dijk FN, de Jongste JC, Postma DS et al. Genetics of onset of asthma. Curr Opin Allergy Clin Immunol 2013; 13: 193-202.
50. Wober-Bingol C. Epidemiology of migraine and headache in children and adolescents. Curr Pain Headache Rep 2013; 17: 341.
51. Gelfand AA. Migraine and childhood periodic syndromes in children and adolescents. Curr Opin Neurol 2013; 26: 262-268.
52. Vogelzangs N, Kritchevsky SB, Beekman AT et al. Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women. J Clin Psychiatry 2010; 71: 391-399.
53. van Reedt Dortland AK, Giltay EJ, van Veen T et al. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr Scand 2010; 122: 30-39.
54. Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord 2008; 10: 144-152.
55. Sylvia LG, Friedman ES, Kocsis JH et al. Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. J Affect Disord 2013; 151: 722-727.
56. Sylvia LG, Salcedo S, Bernstein EE et al. Nutrition, exercise, and wellness treatment in bipolar disorder: proof of concept for a consolidated intervention. Int J Bipolar Disord 2013; 1: 24.
57. Fiedorowicz JG, Solomon DA, Endicott J et al. Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med 2009; 71: 598-606.
58. Feldman NS, Gwizdowski IS, Fischer EG et al. Co-occurrence of serious or undiagnosed medical conditions with bipolar disorder preventing clinical trial randomization: a case series. J Clin Psychiatry 2012; 73: 874-877.
59. Posner K, Brent D, Lucas C et al. Columbia Suicide Severity Rating Scale (C-SSRS). New York, NY: New York State Psychiatric Institute, 2009.